The genes for acetylcholinesterase (ACHE) and butyrylcholinesterase (CHE) are expressed in multiple tumor tissues, including ovarian carcinomas. Both CHE and ACHE genes coamplify in leukemias. To examine the relationship of gene amplification to the expression of these genes in tumors, ACHE and CHE genes and their expression were studied in primary ovarian carcinomas. DNA blot hybridization demonstrated a significant amplification and mutagenesis of both genes in 6 of 11 malignant tumors studied. This was greater or of the same order of magnitude as the amplification of the oncogenes c-rafi, v-sis, and c-fes in these tumors. No amplification was found in normal ovarian tissues or benign ovarian cysts. Xenopus oocyte microinjections, blot and in situ hybridizations, and immuno-and cytochemical staining revealed translatable CHEmRNA and its active protein product in discrete tumor foci. The frequent coamplification in ovarian carcinomas of ACHE and CHE genes implicates cholinesterases in neoplastic growth and/or proliferation. (J. Clin. Invest. 1990. 86:900-908.)
Introduction
The ubiquitous enzyme family of cholinesterases includes two members for which human cDNA probes have been isolated, permitting studies at the genomic level. These are acetylcholinesterase (acetylcholine acetyihydrolase, EC 3.1.1.7, ACHE)' (1) and butyrylcholinesterase (acylcholine acylhydrolase, EC 3.1.1.8, CHE [2, 3] ). Both enzymes can hydrolyze the neurotransmitter acetylcholine (4, 5) and both may be found in large amounts in various embryonic and tumor tissues (6) , concomitant with cell division and DNA synthesis (7) . Using the re-1. Abbreviations used in this paper: ACHE, acetylcholinesterase; BW284C5 1, 1,5-bis(4-allyldimethylammoniumphenyl)-pentan-3-one dibromide; CHE, butyrylcholinesterase; iso-OMPA, tetra isopropylpyrophosphoramide; PCR, polymerase chain reaction.
cently cloned human ACHEcDNA (1) and CHEcDNA (2), we found that the CHE gene is capable of being heritably amplified in humans (8) . Further analysis revealed the occurrence of coamplified ACHEDNA and CHEDNA sequences in genomic DNA from peripheral blood cells of leukemic patients (9) . Altogether, these findings raised the question whether the previously reported high level of expression of the ACHE and CHE enzymes in tumors (10, 1 1) is effected by gene amplification. The rapidly progressing carcinomas of the ovary (12) offer a promising model in which to test this possibility since sections from these tumors exhibit pronounced diffuse cytochemical staining of CHE activities (10) , whereas CHE expression in normal ovarian tissue appears to be confined to maturing oocytes (13, 14 ). Here we demonstrate that both the ACHE and CHE genes are amplified in primary ovarian carcinomas, and are expressed in dividing cells within tumor foci, implicating cholinesterases in tumor growth and development.
Methods
Primary tumor samples. Specimens of primary tumors were obtained at surgery, frozen immediately in liquid nitrogen and stored at -700C until used. Tumor subclassification was performed by standard pathological techniques. Tumor DNA (13) and poly(A)+RNA (15) were prepared as previously detailed. cDNA oligonucleotide primers, and plasmid probes. ACHEcDNA and CHEcDNA probes were enzymatically excised, electrophoretically eluted and precipitated as previously reported (9) . The c-rafi plasmid was from Amersham Corp. (Arlington Heights, IL). v-sis, c-fes, and c-myc (third exon) DNA probes were gratefully received from Opher Gileadi (The Hebrew University, Jerusalem). Oligonucleotide primers complementary to CHEcDNA were according to Soreq and Gnatt (16) and others (17) . Polymerase chain reactions (PCR) were performed with Taq polymerase (BioLabs) according to published procedures (for example, see reference 17).
Blot and in situ hybridization. 32P and 35S-labeled cDNA and plasmid probes were labeled by the multi-prime labeling method (Boehringer Mannheim Biochemicals, Indianapolis, IN) to specific activities of 1-5 X 10 9 dpm/gg DNA using enzymatically restricted and gel electroeluted DNA fragments (2, 8) . DNA (9) and RNA (2) blot hybridizations were performed as previously described, and washes were at 65°C at low ionic strength (0. Enzymatic activity measurements. Cholinesterase activities were measured spectrophotometrically by monitoring the hydrolysis of acetyl-or butyrylthiocholine in the presence of 5,5'-dithiobis(2-nitrobenzoic acid) as previously described (18, 20) . Alternatively, we used the radioactive assay by measuring the release of [3H]acetate from acetylcholine (15) . In both cases, 5-10-Ml samples of 1:10 (weight per volume) tissue or oocyte homogenates in PBS (the equivalent of -I yg tissue or one-half oocyte) were assayed at room temperature. Rates of spontaneous substrate hydrolysis were calculated, averaged and subtracted in both cases. Either 10-5 M 1,5-bis-(4-allyldimethylammoniumphenyl)-pentan-3-one dibromide (BW284C5 1, ACHE specific) or 10-5 M tetra-isopropylpyrophosphoramide (iso-OMPA, CHE specific) were used for selective inhibition experiments. iso-OMPA was preincubated with the samples 40 min before the addition of substrate to ensure complete irreversible binding. Protein determinations were by the Bradford technique, as previously detailed (15) .
Results
When DNA from untreated primary ovarian carcinomas was subjected to restriction enzyme digestion and blot hybridiza- Fig. 1) . In each case of amplification, novel bands were observed in addition to those representing the normal ACHE and CHE genes. The two nonhomologous cDNA probes, which were previously shown not to cross-hybridize under the hybridization conditions employed (9) appeared to colabel novel restriction fragments of the same size when cut with both of the restriction enzymes Eco RI and Rsa I, in DNA samples having the coamplification and under exposure conditions where the normal genes were hardly detectable. In contrast, no fragments of this size were found in DNA samples with normal ACHE and CHE genes (Fig. 1) . It is interesting that the amplified CHEDNA sequences appeared not to include the internal Hind III restriction site characteristic of the normal, introncontaining CHE gene (17, 21) (Fig. 2) . Furthermore, Taq I generated two major fragments of 1400 and 600 basepairs from amplified CHE genes in each of these tumors, similarly with processed, intron-less CHEcDNA that includes such Taq I sites (2, 3) (Fig. 2, (A and B) . To examine whether the abnormal restriction patterns reflected reproducible mutagenesis or processed CHE genes, PCR was performed. For this purpose, oligonucleotide primers were employed from several exon regions as well as across splice sites in the normal CHE gene (see reference 16 for detailed lists of CHEcDNA oligonucleotides and reference 21 for gene map). Both processed CHEcDNA and exon regions from the CHE genes in tumor DNA samples were faithfully amplified. In contrast, we failed to amplify the tumor CHE genes across splice sites, indicating that the amplified CHEDNA included large introns at the expected sites (not shown) and excluding the possibility that it had been inserted into the tumor DNA in processed, intron-free form. (2) . Experimental details were according to previous publications (8, 9) , and washing of filters was at 65 OC in 0.1 X SSC. Ethidium bromide staining of the agarose gels was employed to ascertain that equal amounts of DNA were loaded and electrophoretically separated in each of the lanes. Exposure was for 10 d at -70'C with an intensifying screen. Hind III digested DNA from lambda phage and Hae III digested DNA from 4tx 174 phage served as molecular weight markers. Internal Rsa I restriction sites were found in both of these probes, whereas an Eco RI site exists in CHEcDNA but not in the ACHEcDNA probe employed. Note the intense hybridization signals, reflecting gene amplifications, with both those probes, which were shown to be non-cross-reactive with each other (9 (2) was performed with the enzymes Eco RI (E); Taq I (T) and Rsa I (R). Initiation (AUG) and termination (UAA) sites are noted. The position of the three introns (i 1-3) in the human CHE gene was determined by analysis of genomic clones (16, 17) . (A)n = 3'-poly(A) tail. The coding sequence is represented by shaded area. (C) To ascertain the specificity of hybridization, used DNA blots were rehybridized with a plasmid DNA probe from the c-rafi protooncogene (Amersham Corp.), which also detected amplified DNA sequences in these primary tumors (Table I) . This probe labeled a single, different band in all of the tumors, confirming that the hybridization signals with the ACHEcDNA and CHEDNA probe indeed reflected the true amplification of genuine genomic sequences and were not due to plasmid DNA contaminations.
the third exon from c-myc, a nuclear protein oncogene was observed in any of these primary tumors. There was no apparent correlation between any of these gene amplifications and patient age. 902 Zakut (13) and in other normal developing tissues (Fig. 4 A) . The G,C-rich ACHEcDNA probe (1) gave inconclusive results. However, when poly(A)+RNA from several such ovarian tumors was microinjected into groups of 30 Xenopus oocytes, it directed the synthesis of ACHE activity, sensitive to the selective inhibitor BW284C5 1 (Fig. 4 B) . The level of induced ACHE activity was about twice as high as that previously measured for brain ACHEmRNA (15, 20) . Because of the variability between different oocyte translation experiments (20% deviation between measures) and the small difference between the activities measured in the absence and presence of the CHE-specific inhibitor iso-OMPA, we were unable to determine whether active CHE was synthesized as well (Fig. 4 B) . Therefore, RNA blot hybridizations and Xenopus oocyte microinjections could demonstrate translatable and intact ACHEmRNA and CHEmRNA, respectively.
The presence and expression of the mRNA transcripts produced from the amplified ACHE and CHE genes was further assessed in frozen tissue sections, where the existence of mRNA transcripts could be demonstrated by in situ hybridization, their protein product by immunocytochemical staining with monoclonal anti-ACHE antibodies (23) , which crossreact with CHE (18), and enzymatic activity by cytochemical staining with acetylthiocholine complexes (19) . When consecutive sections from single tumors were subjected to these three analyses, tumor foci in corresponding positions were revealed in which the ACHE and CHE genes were highly expressed, with clear colocalized labeling by the three techniques (Fig. 5) . These foci were limited to malignant tumors bearing the amplified ACHE and CHE genes, and were not observed in any of the other tissue types that were examined. 
Discussion
Several mechanisms have been proposed to account for gene amplification in mammalian genomes. One of these is the insertion and subsequent amplification of a retroviral DNA containing host sequences (24), perhaps in the form of a processed cDNA. However, the amplified CHE genes in ovarian tumors appear to contain introns and are not processed. A second mechanism that has been proposed is the "incidental" amplification of a gene residing close to an amplifiable protooncogene. The core amplification unit including the nmyc protooncogene is, for example, 3,000 kb in size (25) , and the HSTF1 transforming factor, which maps to chromosome band 1 1q1 3, co-amplifies with the INT2 gene in multiple cancerous cells (26). A third possibility is that our amplified sequences contain internal origins of replication, enabling their independent amplification under certain circumstances, similar to the mechanism proposed for the developmentally regulated amplification of the chorion gene clusters in Drosophila (27) . It is unclear which of the two latter mechanisms, if any, might be applicable to the amplification of the CHE and ACHE genes in ovarian carcinomas. Furthermore, it is unclear whether these genes are subject to linked but independent amplification events, or coamplify as a single unit. The observation that restriction fragments of similar lengths from both genes hybridize with both the non-cross-hybridizing cDNA probes could reflect shared genomic sequences and argues for coamplification. Nonetheless, and unlike the HSTF1/INT2 example, there does not appear to be a direct 1:1 correlation be- Table I and Figs. 1 and 2 ) and from fetal human adrenal (Ad), kidney (Ki), liver (Li), and Heart (He) ( 17 wk gestation) were subjected to gel electrophoresis and RNA blot hybridization with [32P]CHEcDNA as previously detailed (2) . Repeated hybridization of the same blot with a non-cross-reactive cDNA probe, termed TH 14, revealed low intensity signals in all lanes (not shown), implying that the intensified labeling of 2.4 kb CHEmRNA in the tumor tissue was specific and was not due to RNA overloading. Ribosomal RNA (28S, 5 kb, and 18S, 2 kb) served for size markers. Exposure was for 5 d at -70°C with an intensifying screen. RNA blot hybridization of poly(A)+RNA from normal ovary revealed no signal at all (13) .
tween the number of copies ofthe two genes in various tumors. Molecular cloning and further chromosomal mapping (28) of the amplified ACHEDNA and CHEDNA in ovarian tumors and their flanking sequences will be required to clarify this issue.
All of the tumors which displayed extensive amplification in the c-rafi, v-sis, and c-fes oncogenes also had high levels of CHE/ACHE genes and high ratios between copy numbers of CHE:ACHE sequences. Other tumor samples had high extents ofCHE/ACHE genes but not of oncogenes, perhaps indicating that the CHE/ACHE genes are amplified earlier in tumorigenesis than the oncogenes and that CHE gene amplification precedes that of ACHE. Interestingly, the CHE gene is expressed earlier than ACHE also in embryogenesis (29) .
RNA blot hybridization, immunochemical and cytochemical staining, and Xenopus oocyte microinjection with tumor RNA all demonstrated that the amplified CHE and ACHE genes are expressed within tumor tissues to yield their catalytically active enzyme products. Regarding the amplified CHE genes, we could show transcription products but remained uncertain as to whether these were translationally active. It is not yet known which promoter directs the expression ofthe ACHE and CHE genes in these tumors or why they are only expressed in a minor fraction of the cells. A large body of information suggests that ACHE and/or CHE activities are transiently expressed during cell growth and/or proliferation in multiple systems (5, 7, 10, 16 (32) . Gene amplification in DDT-exposed insects (33) or in tumors exposed to chemotherapeutic (34) or antibiotic (35) drugs has been correlated with the use of such toxic compounds. An in loco amplification of a defective CHE gene was recently found on the long arm of chromosome 3 in a family exposed to chronic subacute doses of the organophosphorous insecticide methylparathion (8) . Also, organophosphorous pesticides induce chromosome damage in cultured human cells (36) as well as in workers exposed to these poisons (37) . In mice, administration of acetylcholinesterase protects against organophosphate poisoning (36) . Several developmental-related roles have been suggested for cholinesterases over the years (reviewed in reference 6). The amplification of their corresponding genes could hence be indicative of the importance of the fine tuning of cholinergic signaling in cellular differentiation in multiple biosystems. It would be important to find out whether the continuous low-level exposure to common agricultural insecticides might disrupt these processes and support the above described gene amplifications; the correlation between all these phenomena will have to be further examined to assess the abundance of common ACHE and CHE gene amplification in various tumor types, to establish the origin and mecha- 906 Zakut, Ehrlich, Ayalon, Prody, Malinger, Seidman, Ginzberg, Kehlenbach, and Soreq 
